Velan Capital Investment Management LP Has $11.19 Million Stock Holdings in Immix Biopharma, Inc. $IMMX

Velan Capital Investment Management LP lifted its holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) by 46.6% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,085,000 shares of the company’s stock after purchasing an additional 345,000 shares during the quarter. Immix Biopharma accounts for approximately 6.8% of Velan Capital Investment Management LP’s investment portfolio, making the stock its 4th biggest holding. Velan Capital Investment Management LP owned 1.52% of Immix Biopharma worth $11,186,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in IMMX. Jupiter Topco LLC bought a new position in Immix Biopharma in the second quarter valued at $100,816,000. Janus Henderson Group PLC lifted its position in Immix Biopharma by 22.5% during the 1st quarter. Janus Henderson Group PLC now owns 4,802,002 shares of the company’s stock worth $43,698,000 after buying an additional 880,434 shares in the last quarter. BlackRock Inc. acquired a new position in shares of Immix Biopharma during the 2nd quarter worth about $30,827,000. Eventide Asset Management LLC acquired a new position in shares of Immix Biopharma during the 4th quarter worth about $13,331,000. Finally, Marshall Wace LLP grew its holdings in shares of Immix Biopharma by 3,495.4% in the 4th quarter. Marshall Wace LLP now owns 1,978,743 shares of the company’s stock valued at $10,349,000 after acquiring an additional 1,923,708 shares in the last quarter. Institutional investors and hedge funds own 11.26% of the company’s stock.

Immix Biopharma Stock Performance

Immix Biopharma stock opened at $14.01 on Wednesday. The stock has a 50-day simple moving average of $10.79 and a 200 day simple moving average of $9.67. The stock has a market capitalization of $1.00 billion, a P/E ratio of -15.92 and a beta of 0.20. Immix Biopharma, Inc. has a 52 week low of $1.94 and a 52 week high of $15.10.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.01). Research analysts forecast that Immix Biopharma, Inc. will post -0.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on IMMX shares. Needham & Company LLC began coverage on Immix Biopharma in a report on Wednesday, July 22nd. They set a “buy” rating and a $21.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Immix Biopharma in a research note on Friday, July 17th. Bank of America started coverage on Immix Biopharma in a research report on Thursday, June 18th. They set a “buy” rating and a $27.00 price target on the stock. Morgan Stanley dropped their price objective on Immix Biopharma from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 11th. Finally, Citigroup reissued a “market outperform” rating on shares of Immix Biopharma in a report on Friday, August 14th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Immix Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $21.29.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.